Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 08
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
CVS Health Corp
CVS
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$87.95
1.52
1.76%
Últ. Act.: Oct 7, 7:50 PM
$88.01
1.58
1.83%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Privacy Manager
Dividendo:
La fecha límite del dividendo es dentro de 15 días
CVS Health Financials
CVS Health (CVS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.
Vandana Singh
CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal
CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.
Vandana Singh
PRO
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est
Benzinga Newsdesk
PRO
CVS Health Raises FY2026 GAAP EPS Guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 Est
CVS Health (NYSE:CVS) raises FY2026 GAAP EPS guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 analyst estimate..
Benzinga Newsdesk
PRO
CVS Health Q2 Adj. EPS $2.58 Beats $1.85 Estimate, Sales $106.096B Beat $100.114B Estimate
=
Benzinga Newsdesk
These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results
CVS Health (NYSE:CVS) reported upbeat Q1 earnings & raised 2026 guidance. Analysts have positive outlook with price targets raised.
Avi Kapoor
